These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 9220287

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
    Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Beyer J, Jonas U, Kanz L.
    World J Urol; 1996; 14(6):354-9. PubMed ID: 8986035
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer.
    Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J.
    Anticancer Drugs; 1996 Sep; 7(7):795-9. PubMed ID: 8949993
    [Abstract] [Full Text] [Related]

  • 9. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
    Bokemeyer C.
    Oncology; 1998 Sep; 55(3):177-88. PubMed ID: 9560052
    [Abstract] [Full Text] [Related]

  • 10. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
    Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ, Motzer RJ.
    J Clin Oncol; 2005 Sep 20; 23(27):6549-55. PubMed ID: 16170162
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
    Bokemeyer C, Beyer J, Metzner B, Ruther U, Harstrick A, Weissbach L, Kohrmann U, Verbeek W, Schmoll HJ.
    Ann Oncol; 1996 Jan 20; 7(1):31-4. PubMed ID: 9081388
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
    Soulié P, Garrino C, Bensmaïne MA, Bekradda M, Brain E, Di Palma M, Goupil A, Misset JL, Cvitkovic E.
    J Cancer Res Clin Oncol; 1999 Dec 20; 125(12):707-11. PubMed ID: 10592105
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Yamamoto K, Kikuchi Y, Kudoh K, Nagata I.
    J Cancer Res Clin Oncol; 2000 Mar 20; 126(3):168-72. PubMed ID: 10741911
    [Abstract] [Full Text] [Related]

  • 18. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
    Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ.
    Cancer Res; 2003 Jan 15; 63(2):513-21. PubMed ID: 12543810
    [Abstract] [Full Text] [Related]

  • 19. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
    Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ.
    Tumour Biol; 2006 Jan 15; 27(2):71-83. PubMed ID: 16557044
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.